Orchid Pharma Soars 2.9% as Alathur API Facility Aces USFDA Inspection

Orchid Pharma shares jumped 2.9% today following the successful completion of a surprise USFDA inspection at its Alathur API facility. The inspection, conducted from February 10-18, 2025, resulted in seven minor observations, none related to data integrity. The facility, specializing in Cephalosporin antibiotics, also secured renewal of its EU GMP certificate. This dual regulatory success reinforces Orchid Pharma's position as India's only USFDA-approved manufacturer of sterile cephalosporins. The company's commitment to quality and compliance is expected to strengthen its global market presence, particularly in the critical antibiotics segment129.

 

Sources: Moneycontrol, CNBC TV18, Angel One